ATP citrate lyase (ACLY) as a novel anti-cancer drug target for hepatocellular carcinoma

The net 5-year survival rate for patients suffering from liver cancer is less then 20 percent and the number of cases is rapidly increasing in Canada. Unfortunately, currently available oral chemotherapies can only extend median survival by 3 - 4 months making the development of new and effective drug treatments critical. The proposed study aims to pave the way for a new class of drugs to help fight liver cancer and give hope to patients suffering from this deadly disease.

Intern: 
Jaya Gautam
Jianhan Wu
Faculty Supervisor: 
Paola Muti
Province: 
Ontario
University: 
Partner University: 
Program: